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Abstract 
 
Background: Bacterial vaginosis (BV) results from a shift in normal vaginal flora and 
predisposes women to sexually transmitted infections (STI) including HIV. Risk factors for 
BV are not well understood. This analysis seeks to determine the disease frequency of BV, 
assess determinants of BV and quantify time to first BV episode in HIV negative women. 
 
Methods: Baseline and follow-up data from 1066 women was analysed in STATA10. Logistic 
regression was used to determine baseline factors associated with BV and Kaplan Meier 
survival analysis to estimate time to BV episode.  
 
Results:  BV prevalence and incidence was estimated at 48.42% and 81 cases per 100 women 
years respectively. Controlling for age and education, women with Trichomonas vaginalis, 
Chlamydia trachomatis, Herpes Simplex Virus2 and lower socio-economic status were 67%-
380%, 31%-472%, 20%-220% and 4%-91% more likely to present with BV respectively.  
Consistent condom use and being a housewife or student was significantly (p<0.05) associated 
with lower prevalent BV, with a significant interaction between age and education (p<0.05). 
The median time to first BV episode was 9.7 months. 
 
Conclusion: The analysis identifies modifiable risk factors like condom use, injectable 
contraceptives and treatment of STIs which could potentially decrease the high BV disease 
burden.  
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CHAPTER ONE 
 
This chapter gives a brief overview of the research setting and the primary study. It also 
introduces and discusses relevant literature pertaining to Bacterial Vaginosis (BV), and details 
the epidemiological and public health concerns relating to BV. The chapter thus outlines the 
motivation for this analysis.  
Research setting and background 
The Africa Centre for Health and Population Studies is a demographic surveillance site that 
runs a Demographic Information System (ACDIS), which covers approximately 85,000 people 
in 11,000 households in an area of about 438 km2.  ACDIS is a longitudinal prospective cohort 
study of a population within a defined geographic area in rural Umkanyakude district of 
northern KwaZulu-Natal [1]. It was established to describe the demographic, social and health 
impact of the HIV (Human Immunodeficiency Virus) epidemic in a population going through 
a health transition, and to monitor the impact of intervention strategies on the epidemic.  
 
The Africa Centre is one of six partner sites participating in the Microbicides Development 
Programme (MDP: http://www.mdp.mrc.ac.uk) which is sponsored by the United Kingdom 
(UK) Medical Research Council (MRC) and funded by the MRC and UK Department for 
International Development (DfID). The MDP301 randomised, double-blind, placebo 
controlled, phase III clinical trial aims to evaluate the safety and efficacy of PRO2000/5 
microbicide gel in the prevention of vaginally acquired HIV infection. 
At the Africa Centre site sexually active women aged 18 years and over who met the 
eligibility criteria and consented to participate were recruited into the study for a years’ 
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follow-up.  Demographic data was collected once at screening, sexual behaviour data was 
collected once at screening then 4 weekly. Clinical data was collected at baseline and at 
approximately 12 weekly intervals. Amongst other things, women were assessed for Bacterial 
vaginosis (BV) at enrolment then 12, 24, 40 and 52 weeks after enrolment. A secondary data 
analysis of the BV data was conducted to determine the disease burden and assess the factors 
associated with BV using Africa Centre data only, results are presented in this thesis. 
Literature Review 
 
What is Bacterial Vaginosis? 
Bacterial vaginosis (BV) is a term reflective of a combination of factors including a shift from 
the normal vaginal flora which contains predominantly hydrogen peroxide producing 
Lactobacillus species such as L. crispatus and L. jensensii, to a polymicrobial flora that 
includes gram-variable and gram-negative anaerobes such as Gardnerella vaginalis, 
Prevotella spp, peptostretococci, mobiluncus spp and mycoplasmas [2-14].  BV is highly 
variable and both the microbiology of the microbes and the products they produce differ 
considerably between women with BV [13]. BV is often recurrent with the possibility of a 
woman having three or more confirmed (clinically by Amsel’s criteria or microscopically) 
episodes of BV in 12 months [15]. 
Clinical features 
BV clinically presents as a thin, grey-white, watery, offensive and non-inflammatory 
discharge with a vaginal pH greater than 4.5. The discharge may or may not be accompanied 
by vaginal itchiness [16-21]. The odour is due to amines and can be intensified by mixing 
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vaginal discharge with a drop of potassium hydroxide (positive amine test) [15, 21]. The 
discharge presents microscopically as clue cells [14-17, 21].  
Causes of Bacterial Vaginosis 
Microbiological cause 
 
As mentioned above BV is a result of a shift in the normal vaginal microbial flora. Hydrogen 
peroxide producing strains of lactobacilli (L. crispatus and L.Jenseii) produce compounds 
such as lactic acid, acidolin and hydrogen peroxide, through conversion of glycogen by 
oestrogenised vaginal epithelial cells [14, 15, 22-24]. This plays an important role in 
regulating the halide-HPO-myeloperoxidase antimicrobial system and maintaining the acidic 
pH in the vagina [4, 10, 14, 15, 24, 25]. Wilson [15] reports that at pH of 4.0 or less both the 
lactobacilli and the myelopreroxidase system becomes less important as the low pH produces 
an inhibitory effect on bacterial growth such as G.vaginalis this inevitably inhibiting BV. 
Certain risk factors such as sex and menstruation may cause the vaginal pH to rise, facilitating 
anaerobic bacterial growth, which may result in a shift in the characteristic vaginal flora 
resulting in BV [14, 15, 22, 23]. 
 
Although there seems to be an important interaction between lactobacilli, hydrogen peroxide 
production, vaginal pH and overgrowth of BV associated bacteria [10, 15, 22, 26, 27], the 
exact mechanism for the onset of BV is unknown, making it exigent to prevent recurrence. 
Many attempts have been made to ascertain what causes the reduction of these bacteria with 
little success [16-22]. Based on in-vitro studies, G. vaginalis has been suggested to facilitate 
the reduction in essential vaginal lactobacilli in at least some cases of non-specific vaginitis in 
conjunction with anaerobes such as bacteriodes [15, 16, 19-21]. G. vaginalis has also been 
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associated with BV because it has been found in vaginal secretions of 40%-55% of BV 
asymptomatic women and in vaginal discharge of all patients with BV [16, 18, 19, 21]. Recent 
studies have suggested an association between metronidazole-resistant anaerobe Atopobium 
vaginae and BV. This bacteria is uncommon in women without BV [5, 28]   
 
Pathology 
  
G. vaginalis together with A. vaginae, Prevotella spp, peptostretococci Mobiluncus spp and 
mycoplasmas degrade proteins in the vagina to form the foul smelling amines cadaverine, 
putrescine and triethylamine [21, 29]. The combination of amines and organic acids produced 
by the anaerobic bacteria causes the exfoliation of the vaginal epithelial cells, resulting in the 
non-inflammatory vaginal exudates [21]. The disturbed pH allows the gram negative and 
gram-variable bacilli to adhere to the epithelial cells forming the “clue” cells. . It is important 
to note that BV is not caused by a single organism but is rather a shift in the normal 
lactobacillus species to a poly-microbial flora consisting of various anaerobes [16, 19, 21, 30].  
Diagnosis 
Diagnosis of BV is elusive because BV has not yet been exclusively associated with one or 
more particular organisms. As a result, microscopy is a better diagnostic tool than culture. 
Microscopically, BV is diagnosed when “clue” cells are identified after heat fixing of the 
vaginal smear and staining it by Gram’s Method [11, 16-19]. Still the consistency of 
microscopy diagnoses has been debated [31, 32] because it is subjective to the person reading 
the microscope slide (inter-observer variation). It is also dependent on good quality standards 
of specimen collection, preservation and staining before microscopic observation. Clinical 
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diagnosis does not offer a solution to the diagnosis dilemma either, as it is also subjective to 
both patient (recall bias) and clinician (observer bias) thus misdiagnosis remains high in both 
developed and developing countries [11, 16, 18, 19, 21, 28].  
 
Traditionally, the diagnosis of BV based on Amsel composite criteria [11, 32] is made when 
three of the four following criteria are met: homogenous discharge, pH>4.5, positive amine 
test and quantitative determination of clue cells representing more than 20% of vaginal 
epithelial cells [16, 18-20]. This approach was regarded the gold standard until 1983, when a 
publication by Spiegel et al recommended a new method (Nugent’s method) that diagnosed 
BV by the appearance of a gram stained slide [11, 32]. A scoring system was assigned based 
on the presence of Lactobacilli spp, Gardnerela spp and other morphotypes and their relative 
quantities [7, 11, 32]. The use of scoring systems has allowed recognition of a continuum 
between normal vaginal flora and BV as opposed to the all or nothing criteria provided by 
Amsel’s method [11, 33]. Several subsequent modifications have been made to the Nugent 
method finally resulting in the currently used Ison and Hay method [32]. 
 
The Ison and Hay method is based on a diagnostic transition from the ideal lactobacilli flora to 
abnormal flora in five groups ranging from no bacteria (grade 0), normal vaginal bacteria 
(grade I), intermediate shift from normal vaginal flora resulting in an increase in BV 
associated bacteria (grade II) and  predominantly BV associated bacteria (III) to only gram 
positive cocci (grade IV) [11, 34]. The grading is based on the relative quantities of the 
bacteria as defined in Table C6 in Appendix C. However, the sensitivity of Ison and Hay 
scoring is not well defined and grade 0 (no bacteria) might potentially still be BV cases but 
with inadequate vaginal specimen, especially in women who insert fingers in the vagina while 
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washing (finger cleansing). Some authors explain grade 0 as a lack of bacteria after broad 
spectrum antibiotics [11, 33]. Taylor [33] reports that women with grade II BV (intermediate 
shift) are more likely to have some of the symptoms of the Amsel’s criteria than were women 
with normal flora [11, 33]. Grade II and III are diagnostic of  BV but there is no evidence to 
confirm that grade 0 and IV are associated with BV [11].  
 
These methods have been validated in genitourinary medicine clinics in the United Kingdom 
(UK) [11, 33] but extrapolation of results to African settings must be cautionary  because little 
is known about the pattern of vaginal micro-flora associated with BV in Africa [7, 11, 32].  
Prevalence of BV 
BV is the most common vaginal infection affecting women of child bearing age [14, 23, 30, 
31], partly because it is a mixture of unexplained infections. Prevalence rates vary according 
to the population studied and the geographic location. The reasons for the differences in 
prevalence are not completely understood but have been attributed to different vaginal hygiene 
practices associated with culture, ethnicity and socio-economic status [14, 22, 23].  
 
BV prevalence in pregnant women at their first antenatal visit varies from 11% in the United 
States to 24% in Tanzania. Cross sectional community surveys have reported prevalence rates 
of 20%-23%, 24%-37%, 48% and 49% in Burkina Faso and Malawi, Tanzania, Gambia and 
Kenya respectively [7, 14, 25], with higher prevalence in sub-Saharan Africa (20%- >50%) 
than in industrialized countries (10%-30%) [8, 35]. In South Africa, some studies of antenatal 
clinic attendees have given prevalence estimates of 25% whilst others gave estimates as high 
as 52% [12, 25, 31]. In a study of 208 women attending primary health facilities in urban 
KwaZulu Natal, BV prevalence was 35% overall, but 43% in Sexually Transmitted Infections 
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(STI) clinics (n=51), 36% in copolscopy clinics (n=50) and 36% in family planning clinics (n= 
55) [12].  
 
A situational analysis in  2002-3 in KwaZulu Natal province in South Africa revealed that due 
to the diagnostic challenges discussed above, few  facilities were able to accurately diagnose 
BV in women [36], thus it is possible that the disease burden is underestimated.  
Risk factors for BV  
Some  demographic, sexual and socio-behavioural factors including black ethnicity, younger 
age, smoking, contraceptive use and vaginal douching have been associated with an  increased 
the risk of BV [5, 15, 22]. Little progress has been made in identifying and determining the 
relative significance of factors involved in BV acquisition and recurrence [23, 30].  
Vaginal hygiene practices and BV 
The use of genital cleansing products and vaginal inserts is common practice in many 
populations around the world, although they are known to be associated with increased risk of 
STIs, Pelvic Inflammatory Disease (PID), disturbances of the vaginal flora and ectopic 
pregnancies [22-24, 37].  With the introduction of vaginal microbicides, interest in the use of 
vaginal cleansing products  and  inserts has increased [37], yet the practice is rarely evaluated 
in studies of women’s genital infections and symptoms. Consequently, the role that these may 
have on  BV genital symptoms, clinical findings, laboratory testing results, or the incidence of 
infection has not been fully explained [37]. 
 
Studies have shown a positive association between vaginal douching particularly with 
antiseptic agents, and susceptibility to BV [7, 22-24, 26]. Authors have speculated that 
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changes in the vaginal flora due to internal cleansing might allow rapid proliferation of 
potential pathogens during the altered state, increasing the risk of BV. However, reverse 
causality could not be ruled out, where BV causes women to douche in an effort to rid 
themselves of the itchiness, discharge or smell [7]. In contrast, in the Bali STD/AIDS study 
among 625 commercial sex workers, women who internally cleansed the vagina after every 
sex act were less likely to report discoloured vaginal discharge and genital odour. There was 
no significant association between vaginal cleansing and BV in this study [37]. It is note-
worthy that frequent vaginal cleansing may lead to inaccurate clinical diagnosis of BV due to 
the washing out of the vaginal discharge and odour, potentially biasing the association of BV 
and vaginal cleansing towards the null. 
Socio‐economic status and BV 
o Education and BV 
There is evidence that women with low educational attainment are less likely to have good 
reproductive health knowledge. Some studies have also demonstrated an association between 
lower education attainment and the use vaginal inserts and vaginal cleansing products [22, 37] 
which are known risk factors for BV. This may influence a  positive association between low 
educational attainment and increased BV cases, as has been observed in some studies [22, 37].  
o Occupation, income and BV 
In a case control study of 200 women in the United States [22] and in a large population based 
survey of 2,494 women in India [38], a positive association between susceptibility to BV and 
manual occupations and low income was observed. However, the authors speculated that this 
may be a confounded association mainly as a result of vaginal douching in gender 
disadvantaged women in this socio-economic group [22, 38].  
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Sexual activity and BV 
Studies [4, 23, 27, 37] have linked BV with sexual behaviour including a recent change in 
sexual partner, multiple partners and unprotected sex, although in the study of 250 participants 
by Schwebke et al [23] associations did not reach statistical significance. Having a new sexual 
partner has been independently associated with an increase in BV irrespective of the frequency 
of sexual intercourse suggesting that exposure to a new partner is a more important risk factor 
than the number of episodes of intercourse [14, 15, 26, 27]. However worth noting is the fact 
that semen is alkaline and may activate the odour of amines in BV positive women [21]. Thus 
a woman may have had BV before having a new sexual partner and then becomes aware of the 
symptoms after sexual intercourse, leading to a spurious relationship between BV and sexual 
intercourse.  
 
There has been much debate regarding whether or not to classify BV as an STI and this 
discussion remains controversial partly because causal pathogens are not well understood. 
G.vaginalis is also found in the male urethra [20, 21] thus albeit not scientifically proven, [39] 
BV infection is probably transmitted sexually although infectivity with G.vaginalis appears to 
be low [36, 40]. Condom use decreases incidence of BV in women [19, 20], also suggesting 
the possibility of sexual transmission. In contrast, in five out of six trials, partner treatment had 
no benefit for the women in terms of reducing recurrent BV episodes [5, 15, 19]. BV has also 
been detected in women who have never had sex [10, 14]. Consequently BV is not defined as 
an STI although it is highly likely that sexual activity plays a role in acquisition of BV.  
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BV and Sexually Transmitted infections (STIs) 
 
Studies including a systematic review by Wilson, have  revealed that lactobacilli associated 
positively with BV are also positively associated with Neisseiria gonorrhea (NG) and 
Chlamydia trachomatis (CT) infection, but less likely to present with concurrent Trichomonas 
vaginalis (TV) and Herpes Simplex Virus 2 (HSV2) [14, 15, 23, 24]. On the other hand, some 
researchers have reported a strong association between abnormal vaginal ecology and HSV2 
and TV [23, 29, 41] since TV may also be caused by replacement of lactobacilli [24].  
It is hypothesized that BV may be a result of endogenous or sexually transmitted infection 
with an organism that competes or interferes with lactobacilli [41]. On the other hand, 
disturbances in vaginal flora may lead to increased acquisition of other sexually transmitted 
infections [24, 29, 41, 42]. One author suggests that an association between BV and other STIs 
may be a reflection of biological interactions in the vaginal micro flora rather than shared risk 
factors for their acquisition.[14] 
BV and HIV 
 
Cross-sectional studies in North America, Asia and Africa show that women with BV are 
more likely to have and transmit HIV, due to  lack of lactobacilli resulting in increased risk of 
HIV sero-conversion and STI acquisition [4, 13, 14, 24, 27, 29, 37, 41]. However reverse 
causality could not be ruled out. In vitro studies have indicated that low vaginal pH reduces 
HIV infectivity, and hydrogen peroxide producing lactobacilli have a viricidal effect on cell-
free HIV-1 whilst G.vaginalis and other BV associated microbes activate HIV resulting in 
increased HIV expression [13, 24, 41, 43]. In populations with high BV prevalence, BV may 
be one of the most important risk factors of HIV infection.  
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Contraception and BV 
Results from previous research studies have indicated that some forms of contraception may 
be associated with BV. Several studies have shown hormonal contraception to be protective 
against BV [16-21, 23, 24] whilst longitudinal studies of BV incidence have shown an 
increase in BV in women using Intra Uterine Device (IUD) [15, 44]. The exact physiological 
mechanism for effect between IUD and BV is unknown but it is speculated that increased 
oestrogen from hormonal contraceptives may facilitate bacterial lactic acid production by 
increasing levels of available glycogen in epithelial cells, thereby inhibiting BV-associated 
organisms [44]. 
Age and BV  
The presence of lactobacilli (L.crispatus and L. jenseii) has been positively associated with 
being over 20 years of age [15]. Adolescent females represent a menarchal population that is 
newly influenced by reproductive hormones and is also susceptible to BV due to changes in 
vaginal tissues [2, 4, 15]. After menopause, the vaginal environment gradually reverts back to 
the pre-menarchal state. These vaginal physiological variations influence BV prevalence with 
age [2, 4]. However, in one prospective cross sectional study, BV prevalence peaked at around 
30 years, possibility due to infection being incubated and symptoms presenting at a later stage 
[14].  
Sequelae of BV 
Irrespective of its status as a Sexually Transmitted Infection (STI), BV is not a minor 
condition. The sequelae of BV include nonchlamydial and nongonococcal pelvic 
inflammatory discharge (PID), urinary tract infections, endometritis, preterm labour, 
membrane rapture, septicaemia, meningitis, postpartum complications in the infant and 
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neonatal deaths [9, 12-14, 19, 29, 30]. In addition, BV strongly predisposes both pregnant and 
non-pregnant women to acquisition of STIs such as NG, CT and HIV [12, 30, 40]. 
 
The relationship between BV and preterm birth has been demonstrated in at least 12 
epidemiologic studies conducted on five continents among pregnant women at different 
gestational stages [13]. In sub-Saharan Africa, the proportion of pregnancy complications 
attributed to BV is not well studied, hence not ascertained. In a small study in South Africa, 
BV was diagnosed in 55 out of 77 women with pregnancy complications and in 32 of 48 
women with obstetric complications [8]. Even though the study was small, it is evident that 
BV is associated with adverse pregnancy outcomes. This raises a need for further studies into 
the aetiology of BV, its impact on women and ultimately its control, in developing countries. 
Treatment of Bacterial vaginosis 
Treatment of symptomatic BV is usually by administering high doses of metronidazole [11, 
16, 18, 21]. It is worth highlighting this use of antibiotics to treat a condition that is an 
imbalance rather than an infection. This might be the cause of the high rate of BV relapse [10]. 
Since vaginal flora can be in a dynamic state, changing day by day, it is recommended that 
asymptomatic women are not treated [33].  
 
In conclusion, BV is a frequently recurrent, distressing condition mainly prevalent in women 
of child bearing age. It has a poorly defined aetiology, is difficult to treat and prevalence rates 
vary significantly across geographic areas.  It is associated with a considerable proportion of 
pregnancy complications and with increased incidence of STIs and HIV.  
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Statement of the problem and justification for the research  
 
As highlighted in the review above, BV has highly clinically significant sequelae [9, 12-14, 
19, 29, 30], yet there are many unanswered questions about its aetiology making management 
of infection difficult and often idiosyncratic [9, 15-22].  
 
From literature reviews, studies in South Africa have used the Amsel’s criteria and Nugent’s 
scoring method but not the Ison and Hay BV scoring method due to it being a relatively new 
diagnostic scoring method. It is worth while computing prevalence and incidence estimates 
using new diagnostic technologies especially in the African region were such data is not only 
lacking but largely variable.  
 
Routinely collected data in rural KwaZulu Natal through the ACDIS has given high HIV 
prevalence estimates of  27% in women aged 15-49 years, coupled with an incidence rate of 
4.0 per 100 person-years (95% confidence interval (CI) 3.3-4.7) [45, 46]. In a microbicide 
feasibility study of 882 participants conducted in the same area, HIV prevalence and incidence 
rates in sexually active women aged 16-50 years  were approximated at 50% and 12.6 (95% 
CI 8.2-19.6) per 100 women years of follow-up [47].  BV’s positive association with HIV in 
this area with high HIV disease burden makes further research into the aetiology of BV a 
public health priority in order to inform prevention strategies. 
 
Reducing BV incident and prevalent cases in this area, where an estimated 9,057 women 
become pregnant each year in the Hlabisa health sub-district [48] might considerably curb 
adverse pregnancy outcomes attributable to BV.  
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Determining the burden of BV and associated factors is also critical in terms of developing 
effective behavioural change interventions that may be required to curb the disease burden. 
The health services in this area are already overburdened by HIV and the general community 
is within the lower economic bracket with the main source of income being social grants [39, 
48, 49]. Hence maintaining health in this area is of paramount importance to ensure that 
limited financial and health resources are not further strained.  
 
This study seeks to determine the disease burden of BV in rural Northern KwaZulu Natal 
through the use of a large data set of clinical, laboratory and behavioural outcomes. It also 
aims to investigate the factors associated with BV. This analysis is important from both an 
epidemiological and public health perspective, and has particular relevance in this part of 
KwaZulu Natal due to the overall burden of HIV.  
Research question 
 
What is the disease burden of BV and what are the factors associated with the disease in 
sexually active women aged 18 years and over, enrolled in an HIV prevention trial in Northern 
KwaZulu Natal? 
Study objectives 
 
The main objectives of this analysis are as follows: 
 
1. To measure the point prevalence of BV at enrolment into the trial. 
2. To determine whether the following factors predispose women to BV at baseline  
● Demographics                ●Socio-economic status        
● Vaginal hygiene practices    ● Family planning methods  
● Sexual behaviour practices    ●Infection with another STI  
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● An abnormal pap smear 
3. To measure the incidence of BV in women followed up in the trial from March 2006 to 
March 2008 and to quantify the time to first BV episode. 
4. To determine the proportion of asymptomatic BV cases and assess the concordance 
between laboratory diagnosed BV grades and clinical symptoms.  
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CHAPTER 2: METHODOLOGY 
 
This chapter details the study methodology, including data collection and management, 
specimen collection and analysis, data extraction cleaning and analysis. Only the relevant 
methodological issues employed in the primary trial are highlighted in this chapter. 
Comprehensive details on methodology of the primary trial may be obtained from the 
Microbicide Development Programme (MDP) 301 Protocol version 1.3 [47]. 
 
Data was collected in an international multi-centre, randomized, double blind, placebo-
controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO2000/5 gels for the 
prevention of vaginally acquired HIV infection [47]. Local analysis of data was done to 
determine the disease burden of BV, its determinants, and the average time to the first BV 
episode.  
 
Setting of the primary study 
 
The Africa Centre for Health and Population Studies is located in Somkhele in the rural 
district of Umkhanyakude in northern KwaZulu Natal, South Africa. The study area consists 
of land under tribal authority and a township under municipal authority [1] .The MDP trial 
recruited women from the community, using various methods including snowballing and 
enrolled at 3 primary health care clinics. A total of 1,085 women were enrolled into the 
primary study by February 2008.  
Study population 
Women attending the KwaMsane, Mtubatuba and Madwaleni primary health care clinics were 
enrolled into the primary trial using the following eligibility criteria; 18 years and over, 
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sexually active, HIV negative and willing to undergo HIV tests at 12 weeks interval, not 
pregnant nor 6 weeks post-partum, willing to undergo genital exams, having no latex allergy, 
willing to receive condom education and willing and able to give informed consent. Each 
woman was followed up for a total of 52 weeks. 
Study design 
 
For the analysis in this study, a cross-sectional analytical design was used to determine BV 
point prevalence at enrolment, in the study population of 1,085 women and to establish 
associations between baseline risk factors and BV at initiation. BV incidence was determined 
with a prospective cohort design (March 2006 to March 2008) and to compute time to first BV 
episode in women who were BV negative at baseline.  
Sample size considerations 
 
From literature review, BV prevalence has been approximated at around 50%, thus a 
prediction of between 450 and 500 BV positive women was made from the available sample 
size. Following precision calculations given below, a sample size of 1085 women would give 
enough precision to ascertain associations between BV and various risk factors at 5% 
significance level. With this sample size, the precision (half-width of the 95% confidence 
interval) of results is approximated at 0.03: 
Precision= 1.96√(p(1-p)/N),  
p is unknown and set at worst case scenario of 0.5, N is sample size (1,085) 
The fixed sample size of 1,085 will not bear any limitation on analysis, since it is large enough 
to detect any associations if they indeed exist. 
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Data collection  
Demographic data was collected at the screening visit which was up to a maximum of 6 weeks 
prior to enrolment. Sexual behaviour data including number of sexual partners, type of partner 
and number of sex acts were collected at baseline and at 4 weekly intervals. Clinical data 
including vaginal specimens, self-reported symptoms and clinical signs observed during pelvic 
examination were collected at baseline and at approximately every 12 weeks. Data collection 
methods employed included the use of structured sexual behaviour, clinical and demographic 
Case Report Forms (CRFs), and laboratory reports generated from testing of biological 
specimens collected from the participants at baseline and at follow-up visits. Sample CRFs are 
appended in appendix D. 
Specimen collection, transportation and processing 
 
Specimens were collected from all participants regardless of clinical symptoms. Specimens 
were transported to laboratories located in Durban, about 220kms away from the site and 
initial processing was done within 24 hours. 
 
Cervical swabs (Gen-Probe Aptima- Gen-Probe Incorporated, San Diego, CA, USA) and 
vaginal swabs (BD ProbeTec - IVD, Becton, Dickinson and Company, USA) were collected at 
baseline and at week 24 and inserted in transport media during transportation. These were 
tested for NG (Gen-Probe Aptima), CT (Gen-Probe Aptima) and TV (PCR). Whole blood was 
also collected 12 weekly and tested for syphilis (Rapid Plasma Reagin - B&D MacroVue 
followed by Treponema pallidum hemagglutination assay - Omega Diagnostics Immutrep), 
and HSV2 (Focus assay). Cervical smears were collected at baseline only, preserved using 
cytofix and examined microscopically for abnormal cervical cells 
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BV diagnosis 
A high vaginal smear was collected at enrolment and at approximately 12 week intervals.. The 
slides were transported in a protective jacket to the laboratory. Vaginal flora was characterised 
by Gram’s stain method and slides viewed under a microscope. Presence of “clue” cells was 
used to determine BV status through the Ison and Hay BV scoring method as indicated in 
Table C6 (Appendix C). To validate and verify results, 5% of all specimens were read by two 
individuals who were blinded to each other’s result. BV outcome was broadly defined as BV 
negative and BV positive where grade III was a positive result and Grade 0, I, II and IV were 
defined as BV negative.  
  
Data management 
Data were double entered into an Access front end database in SQL server that was centrally 
designed by the UK MDP CTU for use by all primary study sites. Data were verified to see if 
the two entries corresponded before saving. Inconsistencies were addressed at data collection 
level and data entry and were resolved within 14 days of the visit date. Clinic managers 
conducted 100% quality control of all data forms at each clinic before the forms were sent for 
data capture. Quality checks for inconsistencies and missing data were also run fortnightly 
centrally by the UK MDP CTU. Any inconsistencies were sent to the site to be resolved within 
14 days. Quarterly monitoring and yearly audits were conducted on the clinical site and testing 
laboratories to ensure that the conduct of the study was according to ICH GCP and GCLP 
guidelines and data obtained was valid and accurate. All participating laboratories were 
enrolled into Quality Assurance Programs with Contract Laboratory Services (CLS) and 
National Health Laboratory Services (NHLS), South Africa. 
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Staff training 
To ensure standardised and accurate data collection from the interviewers, extensive training 
was provided by both the site senior staff as well as by the MDP CTU. Training included 
interview skills, CRF completion, genital exams and specimen collection, as well as ICH and 
South African GCP, GCLP and Ethics principles. Training evaluations were conducted and 
written exams completed to assess comprehension prior to being delegated responsibilities on 
the trial. 
 
Validity and reliability checks 
To assess the validity and reliability of the research methods employed in the primary study, 
feasibility (2004) and pilot (2005) studies were conducted and these are detailed in the MDP 
301 protocol [47]. 
 
Data Processing and Data Analysis Methods  
Data was analysed using Intercooled Stata 10 (Stata Corporation, College Station, Texas, 
USA).  
 
Outcome variables 
BV outcome: was defined as BV negative or BV positive.   
Explanatory variables/ risk factors  
Socio-economic demographics  
• age* (categorical variable), religion* (categorical- nominal), education*  
(categorical – ordinal - highest level attained will be considered) and type 
of employment (categorical- nominal - manual or non manual). 
Vaginal cleansing practices  
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• use of vaginal inserts (binary- yes or no), frequency and time of insertion 
and type of insert, frequency and timing of washing. 
Family planning methods  
• (categorical- traditional oral/inserts, barrier, oral, injectables, sterilisation, 
condom and post menopausal). 
Sexual behaviour practices  
• Type of partner – long term or any other once off or short term partner 
number of partner/s (discrete), condom use (categorical – never, always, 
sometimes), frequency of sex acts in the last week and last month (discrete) 
and age of sexual debut (categorical). 
Infection with another STI  
• infection with NG, CT , HSV2 and TV* 
Having an abnormal pap smear  
• LSIL HSIL and ASC 
Clinical symptoms  
• Discharge (yes/no); offensive discharge; discharge source 
(vaginal/cervical/cervico-vaginal) and pH >4.5  
*Possible confounding variables are asterisked and assessed further during analysis. 
 
Data extraction 
 
Eight datasets comprising of demographics, condom use, sexual debut, contraception, sex acts, 
vaginal practices, genital exam and laboratory data were extracted from the main MDP 
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database. The datasets were saved as text (.txt) files and imported individually into STATA 
10. 
Data cleaning 
 
Each dataset was individually cleaned. Variables were tabulated, cross tabulated, summarised, 
graphed and browsed to check for inconsistencies and outliers. Distribution of various 
variables was assessed. Inconsistent data as well as clinically implausible data was checked 
against the Case Report Forms (CRF) to verify and correct data. Inconsistent demographic and 
family planning data was also verified and updated on the dataset. Missing variables were 
manually checked on the CRF as well as on the laboratory logs to confirm and update data. 
Specimens which were missed or lost and recollected at a later date were added to the initial 
time point, by replacing the missing result with the result for the re-analysis/re-collection. A 
total of 40 individual test results were updated. The age variable was compared to date of birth 
to verify if age was correct. Variables such as, but not limited to, age, education status, type of 
employment, frequency of condom use and frequency of sex acts was categorised based on 
existing literature.  Unadjusted Odds Ratios (UOR) and clinical reasoning were also used to 
inform which categories to combine without distorting results. The various categories were 
labelled accordingly before analysing them. After categorisation the numbers of participants in 
each group were assessed to check if they were large enough to determine statistical 
significance. The best determined categories were then used for analysis. All laboratory tests 
were categorised as binary (positive or negative). For survival analysis, duplicates were 
identified and removed before reshaping data into wide format. For the Kaplan Meier analysis, 
a positive BV laboratory result after enrolment was defined as a failure and data was set to 
survival data.   
23 
 
Data analysis 
 
Before analysis, the different datasets were merged on trial number which was the participant 
unique identifier, into one main dataset that was used for analysis.  
 
The flow of participants to the final datasets that were used in the different analysis is shown 
in Figure 2.1 below.  The 68 participants who had missing data on one or more categories in 
the final model were described and their effect on the final model was assessed by adding 
them into the final model as a missing category. Log likelihood ratios and change in Odds 
Ratios, 95% Confidence Intervals and standard errors were assessed to measure the impact of 
not having these participants on the association between BV and independent explanatory 
variables.  
Descriptive statistics: 
 
The distribution of variables in the population according to BV status was assessed. The 
distribution of baseline explanatory variables was compared between the BV positive and BV 
negative categories using the t-test for continuous variables, Unadjusted Odds Ratio (UOR) 
and Chi-squared and Fischer’s exact for categorical variables [50]. Summary statistics 
including but not limited to means, medians and ranges were computed per BV status. Results 
were presented in the form of flow charts, pie-charts, bar charts, line graphs and tables. 
Variables were assessed for colinearity [50] to ensure that correlated variables are not both 
included in the main regression model. 
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Figure 2.1: Flow of women aged> 18 years enrolled between March 2006 and March 
2008 in the MDP 301 in rural KwaZulu Natal, for data extraction and final analysis 
526 for survival analysis 
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Analytical statistics:  
 
All results were presented with significance level and confidence interval. Any result with 
P<0.05 was considered statistically significant unless otherwise stated. 
 
The study objectives were achieved as detailed below: 
 
1)  To measure the point prevalence of BV at enrolment into the trial (week 0). 
Prevalence was calculated as the number of BV positive cases/ total study population at 
enrolment 
2) To determine whether the following factors predispose women to BV  
● Demographics                ●Socio-economic status        
● Vaginal hygiene practices    ● Family planning methods  
● Sexual behaviour practices    ●Infection with another STI  
● An abnormal pap smear 
Null hypothesis: there is no association between the above factors and BV outcome 
After univariate analysis, variables that were significant in the univariate model at 15% 
(p=0.15) were individually added into the final multivariate logistic model, observing change 
in OR to assess potential confounders and interactions. A less conservative significance level 
of 15% was used to ensure that any confounded variables in the univariate analysis would not 
be missed out of the multivariate analysis. Stratification analysis was done to control for 
potential confounders. Interaction terms were generated and introduced into the model where 
necessary. Backward elimination and forward selection procedures were employed for 
comparison with the final model built.  Log likelihood ratio tests were also done to determine 
the best parsimonious model by comparing the log likelihood of the model before and after 
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addition of a variable. Results from the multivariate model were reported at 5% significance 
level (p=0.05) 
3) To measure the incidence of BV over the 2 year period from March 2006 to March 
2008 and to quantify time to first BV episode.  
Kaplan Meier Survival analysis [51] was used to compute incidence and to determine average 
time to first BV episode. Survival probability graphs were computed to estimate the 
probability of survival as a function of time from entry into the trial. The period between the 
starting time and the date of the last follow-up observation before the analysis was recorded 
for each subject. The percentage of women still BV negative at the end of each specified week 
of visit was used to estimate the probability that a woman will be still BV negative at the end 
of any given week/visit.   
4) To determine the proportion of asymptomatic BV cases and assess the concordance 
between laboratory diagnosed BV grades and clinical symptoms.  
Null hypothesis: there is no difference in symptoms between women with or without BV 
Symptoms were categorised into the number of symptoms presenting and vaginal discharge 
was further assessed to determine the source of discharge as vaginal, cervical, cervico-vaginal 
and ‘not possible to tell’. Descriptive analysis was used to quantify the proportion of 
asymptomatic and symptomatic cases in the different BV grades. A proportions test was done 
to assess whether there was a significant difference in the proportion of symptomatic BV 
positive women compared to BV negative women [50]. 
 
The results obtained from this analysis were collated and summarised and are presented in the 
next chapter.  
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Ethical Considerations 
The primary study documentation was submitted to the UKZN Biomedical Ethics Committee 
and to the South African Medicines Control Council for approval and approval was granted, 
approval number T111/05 and N2/19/8/2(1629) respectively. No additional approval was 
required from this committee for this study as it is a secondary data analysis. The protocol for 
this secondary data analysis was submitted to the University of Witwatersrand Ethics 
Committee for educational purposes. Approval was granted, approval number M080332. 
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Chapter 3: Results 
 
This chapter details the results obtained from the methodology above. Short summaries are 
included to consolidate the tables and graphs.  
Description of the study sample  
The mean and median age for the 1,066 participants (as per participant flow) was 34.86 
(standard deviation 11.57) and 35.0 years respectively with an inter-quartile range of 24-45 
years. There was no significant difference in age between BV positive women (35.41yrs) and 
BV negative women at baseline (34.35yrs) p=0.13. The age ranges were also similar for BV 
positive (18-69yrs) and BV negative (18-65yrs) women. 
 
 All women were in partnerships with the majority in long term relationships; only 12 women 
(1%) reported having a casual partner, defined as a sexual encounter with a partner other than 
the long term partner. Although condom use was relatively low with 568 (56.8%) of women 
reporting never having used a condom, consistent use was high with 401 (92.8%) of the 432 
women reporting condom use, always using a condom. This was well correlated with the 
women reporting using a condom at the last sex act. Eight hundred and thirty seven (78.6%) of 
participants had their sexual debut between ages 15-19 yrs. Of the 600 women (56.29%) on 
contraception, 52% were on injectables. Only 7 women (0.64%) reported ever using vaginal 
inserts, whilst 207 (19.42%) reported washing the vagina after sexual intercourse. 
 
The number of assets and fuel source used in the household were well correlated, with most 
people who reported to own no assets using wood as source of fuel. The most prominent  
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religion was Zionist (46.25%). Fifty one percent (51%) of women had secondary or tertiary 
education and only 191 (17.93%) of the women were employed.  
Table 3.2: Description of baseline characteristics of 1066 women enrolled in the MDP301 trial in rural 
KwaZulu Natal between March 2006 and March 2008 and their unadjusted association with prevalent BV 
Sample characteristics Total 
sample 
BV Neg 
(%) 
BV Pos 
(%) 
Total 
Pos/Neg 
OR  
(95% C.I) 
p-
value 
Age 18-34 
1066 
292   (54.89) 240 (45.11) 532  
35+ 261   (48.88) 273 (51.12) 534 1.27 (1.00-1.62) 0.050 
Education Primary 
1066 
251   (47.90) 273 (52.10) 524  
Secondary 302  (55.72) 240 (44.28) 542 0.73 (0.57-0.93) 0.011 
Religion Christian 
1066 
101  (51.01) 97   (48.99) 198  
Zionist 252  (51.12) 241 (48.88) 493 1.0   (0.72-1.38) 0.98 
Shembe 134  (51.34) 127 (48.66) 140 0.99 (0.68-1.43) 0.94 
None 11    (50.0) 11   (50.0) 22 1.04 (0.43-2.51) 0.93  
Other 55    (59.78) 37   (40.22) 92 0.70 (0.42-1.56) 0.16 
Employment Unemployed 
1065 
265   (48.98) 276 (51.02) 541  
housewife 160   (55.94) 126 (44.06) 286 0.76(0.57-1.01) 0.057 
employed 95     (49.74) 96   (50.26) 191 0.97(0.70-1.35) 0.858 
student 33     (70.21) 14   (29.79) 47 0.41(0.21-0.78) 0.007 
Employment 
type 
Unskilled 
184   
28     (14.66) 24    (12.57) 52  
Household 19     (9.95) 11    (5.76) 30 0.87 (0.45-1.68) 0.684 
Services 47     (24.61) 55   (28.80) 102 1.00 (0.58-1.72) 0.997 
Number of 
household 
assets 
4 
1066 
77    (55.40) 62   (44.60) 139  
3 176  (54.66) 146 (45.34) 322 1.03 (0.69-1.54) 0.884 
2 119  (46.85) 135 (53.15) 254 1.41 (0.93-2.13) 0.106 
1 146  (51.96) 135 (48.04) 281 1.15 (0.76-1.73) 0.507 
0 35    (50.0) 35   (50.0) 70 1.24 (0.70-2.21) 0.461 
Fuel source Electricity 
1066 
202  (57.55) 149 (42.45) 351  
Gas 42    (47.73) 46   (52.27) 88 1.48 (0.93-2.37) 0.098 
Paraffin 72    (51.06) 69   (48.94) 141 1.30 (0.88-1.92) 0.191 
Wood 237  (48.77) 249 (51.23) 486 1.42 (1.08-1.88) 0.012 
Contraception No 1066 215  (46.14) 251 (53.86) 466   
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Sample characteristics Total 
sample 
BV Neg 
(%) 
BV Pos 
(%) 
Total 
Pos/Neg 
OR  
(95% C.I) 
p-value 
Contraception Pills 1066 26    (44.07) 33   (55.93) 59 1.09 (0.63-1.88) 0.76 
injectables 186  (59.24) 128 (40.76) 314 0.59 (0.44-0.79) <0.001 
sterilised 44    (50.57) 43   (49.43) 87 0.84 (0.53-1.32) 0.447 
condom 82    (58.57) 58   (41.43) 140 0.61 (0.41-0.89) 0.010 
Sex debut-yrs <15 
1064 
33    (47.83) 36   (52.17) 69  
15-19 448  (53.52) 389 (46.48) 837 0.80  (0.49-1.30) 0.36 
20+ 72    (45.57) 86   (54.43) 158 1.09  (0.62-1.92) 0.75 
Casual Partner No 
1066 
550  (52.18) 504 (47.82) 1054  
Yes 3       (25.0) 9     (75.0) 12 3.27 (0.88-2.16) 0.076 
General 
condom use 
Never 
1000 
281  (49.47) 287 (50.53) 568  
Sometimes 15    (48.39) 16   (51.61) 31 1.04  (0.51-2.15) 0.91 
Always 223  (55.61) 178 (44.39) 401 0.78  (0.60-1.01) 0.06 
Condom use at 
last sex act 
No 
1064 
370  (50.75) 359 (49.25) 729  
Yes 182  (54.33) 153 (45.67) 335 0.87  (0.67-1.23) 0.28 
Sex last 7days Yes 
1000 
361  (51.28) 343 (48.72) 704  
No 158  (53.38) 138 (46.62) 296 0.92 (0.70- 1.21) 0.544 
Wash after sex No 
1066 
454  (52.85) 405 (47.15) 859  
Yes 99    (47.83) 108 (52.17) 207 1.22 (0.90-1.66) 0.194 
Syphilis  Negative 
1066 
525  (52.24) 480 (47.76) 1005 1 
Positive 28    (45.90) 33   (54.10) 61 1.29  (0.77-2.16) 0.337 
Neisseria 
gonorrhoea  
Negative 
1066 
510  (51.78) 475 (48.22) 985 1 
Positive 43    (53.09) 38   (46.91) 81 0.95  (0.60-1.49) 0.821 
Chlamydia 
trachomatis 
Negative 
1066 
533  (52.62) 480 (47.38) 1013 1 
Positive 20    (37.74) 33   (62.26) 53 1.83  (1.04-3.24) 0.037 
Trichomonas 
vaginalis 
Negative 
1066 
510  (54.78) 421 (45.22) 931  
Positive 43    (31.85) 92   (68.15) 135 2.59  (1.76-3.81) <0.001 
Herpes Simplex 
virus 2 
Negative 
1065 
208  (59.77) 140 (40.23) 348  
Positive 344  (47.98) 373 (52.02) 381 1.61  (1.24-2.09) <0.001 
Pap Smear Negative 
1010 
477  (92.08) 41   (7.92) 518  
Abnormal 444  (90.24) 48   (9.76) 492 1.26  (0.81-1.95) 0.303 
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1. Prevalence of BV at enrolment into the trial 
Overall, at enrolment 513 out of 1066 women were diagnosed with BV giving a baseline 
prevalence of 48.42%, (CI: 45.40% – 51.43%). The pie-chart below shows the prevalence of 
each BV grade. Of the 51.58% of women who were BV negative, 27.97% had normal vaginal 
flora, 19.52% had intermediate flora whilst 2.88% had no bacteria. 
 
 
 
 
 
2. Determinants of BV 
 
i. BV and STIs 
Table 3.1 shows the prevalence of each STI stratified by baseline BV. The overall baseline 
prevalence rates were estimated at 5.72% for syphilis, 7.60% for NG, 4.96% for CT, 12.66% 
for TV and 67.62% for HSV2. Of these four, BV was statistically significantly associated with 
TV, CT and HSV2, after adjusting for other factors such as age, education, employment and 
condom use in Table 3.2.  
2.88%
27.97% 
19.52% 
48.42% 
1.21% 
 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Figure 3.1: Prevalence of BV per BV Ison and Hay diagnosis grade in 1066 HIV 
negative women at enrolment into an HIV prevention trial in KwaZulu Natal  
32 
 
Table 3.2: Multivariate analysis of factors associated with BV determined through 
Logistic regression analysis, in women aged 18 years and above enrolled in a 
microbicides trial during March 2006 and March 2008 in rural KwaZulu Natal 
 
 
Women with TV and CT were more than twice as likely to be infected with BV [Adjusted 
Odds Ratio (AOR) 2.52 (95% Confidence Interval (C.I.):1.67-3.80) and 2.49 (95 % C.I: 1.31-
Sample characteristics  
N=998 
AOR 
 
95% Confidence 
Interval p-value 
Age and 
education 
Primary and 
age<35 years 1     
Secondary and 
age>34years 0.49  0.26 ‐ 0.95  0.035 
Employment Unemployed 1   
housewife 0.65  0.47 ‐ 0.91  0.012 
employed 0.87  0.60 ‐ 1.26  0.462 
student 0.43  0.21‐ 0.89  0.023 
Fuel source Electricity 1   
Gas 1.56  0.94 ‐ 2.60  0.084 
 Paraffin 1.40  0.91 ‐ 2.17  0.126 
Wood 1.41  1.04 ‐ 1.91  0.026 
Contraception No 1   
Pills 1.14  0.64 ‐ 2.03  0.668 
 injectables 0.66  0.48‐ 0.91  0.011 
sterilised 0.83  0.51 ‐ 1.35  0.463 
Condom use Never 1   
Sometimes 1.01  0.47 ‐ 2.15  0.987 
Always 0.68  0.52 ‐ 0.90  0.007 
TV Neg 1   
 Pos 2.52  1.67 ‐ 3.80  <0.001 
CT Neg 1   
 Pos 2.49  1.31 ‐ 4.72  0.005 
HSV2 Neg 1   
 Pos 1.63  1.20‐ 2.20  0.002 
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4.72) respectively]. Those with HSV2 were 63% [p=0.02 (95 % C.I: 1.20-2.20)] more likely to 
have BV. 
 
ii. BV and socio-economic demographics 
Age was initially assessed assed as a continuous variable, then later categorised into a binary 
variable (above 34 years and 34 years and below) given that literature has highlighted BV 
peaking in the thirty year olds and also through stratified analysis of the 5 year interval group 
categories. At univariate level both age and education were statistically significantly 
associated with BV but both variables lost significance when introduced into the multivariate 
model adjusting for presence of an STI. Further analysis revealed a borderline significant 
interaction (p=0.04) between age and education introduction of which resulted in an 
improvement in the goodness of fit of the model to explain factors associated with BV. Being 
both older than 34 years with secondary education [AOR= 0.49 (C.I: 0.26-9.95)] significantly 
reduced the odds of having BV, compared to women who were younger than 35 years with 
primary education (Table 3.2). 
 
Being a student AOR= 0.43 p=0.02 or housewife AOR = 0.65 (C.I:0.47-0.91) were 
statistically significantly associated with a lower prevalence of BV, unemployed respectively. 
For those employed, the type of employment did not appear to be associated with BV (p>0.05) 
 
In this analysis fuel source was a proxy for socio-economic status [1] and the results showed 
that women with a lower economic status (using wood for cooking) independently were 41% 
(AOR= 1.41, C.I: 1.04-1.19) more likely to be BV positive compared to women who used 
electricity (higher socioeconomic status).  
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iii. BV and condom use 
In the univariate analysis condom use as a form of contraception was highly significantly 
protective [Unadjusted Odds Ratio (UOR) 0.61 (C.I: 0.41-0.89)] against BV. On the other 
hand, reportedly using a condom at last sex act and overall condom use categorised as yes or 
no were not statistically significantly associated with lower BV prevalence. Condom use for 
contraception was highly correlated with always using a condom. Out of 140 women who 
reported using a condom for contraception 117 (83.57%) reported always using a condom thus 
both variables could not be assessed together in the multivariate model. Contraceptive use was 
further categorised into 4 strata with condom use as no contraception, in light of having a 
number of women in the other contraceptive categories also reporting sometimes and always 
using condoms. Subsequently, the 4 strata contraception variable and condom use as never, 
sometimes, always were introduced into the multivariate model and this significantly 
increased the model goodness of fit. Consistent condom use had a protective effect of 32% 
AOR=0.68 (C.I: 0.52- 0.90) whilst inconsistent condom use had no effect on BV after 
controlling for other variables.  
 
iv. BV and family planning methods 
Using injectable hormonal contraception AOR=0.66 (C.I:0.48-0.91), reduced the odds of 
prevalent BV compared to women who were not on contraception controlling for age, 
education, employment and condom use. 
  
v. BV and sexual behaviour practices 
There was low exposure reporting on casual partners with only 12 women reporting having a 
casual partner thus effects of this variable on the odds of having BV could not be assessed. 
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There was no statistically significant association between prevalent BV and sexual debut and 
having had sex in the last 7 days compared to in the last 4 weeks 
 
vi. BV and vaginal hygiene practices 
There was no significant association between presenting with prevalent BV and washing the 
vagina after sex as well as with religion (Table 3.1). Seven women reported use of vaginal 
inserts for vaginal cleaning or tightening thus effect of inserts on BV could not be assessed 
 
Missing values in the regression model 
Of the 68 participants who did not contribute to the main analysis, 66 of these were missing a 
condom category, one had a missing HSV2 result and one had a missing employment status. 
They had a mean age of 31.4 years (S.D 12.3), median age 26.5 years (IQR 21-43). The 
profiles on sexually transmitted infection showed that 44 (66.67%) had HSV2 while 3 (4.5%) 
were CT positive 59 (89.4%) and did not have TV. These characteristics were consistent with 
those of the main cohort used in the final Logistic regression model. Thirty two women 
[48.48% (95% C.I: 35.99-61.11)] out of 66 had prevalent BV.  
 
There was a 5.38% reduction in the overall model log likelihood value on addition of the 
category with the individuals missing condom use, into the main model. Despite the decrease 
in model goodness of fit, all the variables that were significant before adding the missing 
group remained significant, with a negligible change in the standard errors as well as in the 
95% C.I. There was also a vast overlap in the 95% C.I. with and without the missing values. It 
was concluded that there was no added value in inclusion of these participants in the final 
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model and based on the log likelihood, the model without the missing values was considered 
the most parsimonious and informative model of best fit. 
 
3. Incidence and survival time 
 
Of the total 553 women who were BV negative at enrolment, 27 had either a missing endpoint 
date or endpoint BV results, remaining with 526 women available for incidence calculations. 
A total of 526 baseline BV negative women were followed up providing 313 women years, 
with a total of 255 incident cases. Kaplan Meier analysis gave an estimated overall follow-up 
time mean, median and range of 7.2, 5.88 and 1.44 – 15.12 months respectively. The estimated 
incidence rate was 81 cases per 100 women years (95% C.I: 72 – 92 per 100 women years) 
with a median time to an incident BV case of 9.72 months, inter-quartile range of 4.56-14.28 
months. The incidence rate peaks every subsequent 3 month follow-up period and by 40 
weeks just over 40% of the total cohort had had a BV incident case (Table 3.3 and 4).  
Table 3.3: Period/Cohort BV incidence rates during follow-up of 526 women who were 
BV negative at enrolment between March 2006 and March 2008 in rural KwaZulu Natal 
  
 Cohort (weeks)     person-time total failures     rate (per women year) 95% C. I 
 (0   - 12]      130.01   57  0.44   0.34 0.57 
(12 - 24]      88.24   116  1.31   1.10 1.58 
(24 - 40]      55.87   21  0.38   0.25 0.58 
(40 -   52]      34.13   46  1.35   1.01 1.80 
(52-65]       4.76   15  3.15   1.90 5.23 
Total       313.01   255  0.815   0.72 0.92 
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Table 3.4: BV survival function/probabilities of women at different time points of follow-
up following enrolment into an HIV prevention trial between March 2006 and March 
2008 in rural KwaZulu Natal.  
Visit 
week 
Number  of 
women at visit 
Number 
Positive 
%  of 
Positives 
Survivor 
function 
95 % C.I 
0 526   1  
12 495 126 25.45 0.89 0.86 - 0.91 
24 342 64 18.71 0.64 0.60 - 0.68 
40 204 47 23.04 0.59 0.54 - 0.63 
52 124 18 14.52 0.43     0.38 - 0.48 
 
 
Figure 3.2 shows the survival curve to first BV episode which together with tables 3 and 4 
indicate that the percentage of BV positive people tended to have peaks and troughs at 
alternate 3 monthly visits. The graph also shows that incidence is highest in the first half year 
illustrated by the steepness of the graph over this time period. The cohort/period incidence 
rates (Table 3.3), calculated as the incidence rate for a given continuous portion of the total 
follow-up time, were highly variable with the incidence significantly peaking at period 12-24 
and 40-52 weeks [1.31 (95% C.I:1.10 - 1.58) and 1.35 (95% C.I: 1.01 - 1.80)]. The same result 
is observed in Table 3.4 with the percentage of BV positive people showing a cyclical pattern. 
Worth noting is the decrease in person time as time progresses, mainly due to data being used 
before closure of the primary trial. After week 52, only 43% of the total cohort had not 
experienced a BV episode as indicated by the survivor function which shows the proportion of 
people who had not had an incident BV case [survivor function:  0.43 (95% C.I: 0.38 - 0.48)]. 
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Figure 3.2: Kaplan Meier curve of time to first BV episode in women who were BV 
negative at enrolment into a microbicides trial in rural KwaZulu Natal. 
 
 
4. Proportion  of asymptomatic BV  cases and  concordance between  laboratory 
diagnosis and clinical symptoms  
 
BV was diagnosed on the basis of a laboratory Ison and Hay grade III result. Clinical 
symptoms included vaginal discharge with a fishy smell, alkaline pH <4.5, cervical discharge 
and discharge from both the vagina and the cervix (cervico-vaginal discharge). In Figure 3.3, 
any combination of symptoms was considered as the group with two symptoms and with three 
symptoms. Of the total population, 97 participants presented with symptoms, 60 (61.86%) had 
vaginal discharge; 45 (46.88) of which was offensive and 61 (67.03%) had a vaginal ph>4.5.  
Worth noting is that symptoms were experienced in both the BV negative and BV positive 
groups (Table 3.5).  
0.00 
0.25 
0.50 
0.75 
1.00 
0 0.5 1 1.5 Analysis time (years)
Kaplan-Meier survival estimate
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Table 3.5: Proportion of women with or without BV presenting with symptoms at 
enrolment during March 2006 to March 2008 in rural KwaZulu Natal. 
Symptoms Baseline BV Total N in 
group 
n (%) 95% C.I 
Discharge  Yes BV neg 552 49      (8.88) 6.49     -    11.25 
BV pos 512 48      (9.38) 6.84     -    11.91 
Ph >4.5 BV neg 44 29      (65.91) 51.33   -    80.49 
BV pos 47 32      (68.09) 54.25   -    81.92 
Offensive 
discharge 
Yes BV neg 48 24      (50.00) 35.33   -    64.67 
BV pos 48 21      (43.75) 29.19   -    58.31 
Source of 
discharge 
Vaginal BV neg 49 26      (53.06) 38.76   -    67.36 
BV pos 48 34      (70.83) 57.67   -    83.99 
Cervical BV neg 49 3        (6.12) -0.75    -    12.99 
BV pos 48 7        (14.58) 4.36     -    24.80 
Cervico-
vaginal 
BV neg 49 17      (34.69) 21.06   -    48.33 
BV pos 48 6        (12.50) 2.92     -    22.08 
Not possible 
to tell 
BV neg 49 3        (6.12) -0.75    -    12.99 
BV pos 48 1        (2.08) -2.05    -    6.21 
 
Of the 513 women who had BV, 465 (90.64%) had no symptoms, 12 (2.34%) had one 
symptom, 18 (3.51%) had two symptoms and 18 (3.51%) had three symptoms. One or more 
symptoms were experienced in 49 (8.88%) of women who were BV negative at baseline 
(Figure 3.3).  
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Figure 3.3: Proportion of BV negative and positive women aged 18 years and above in 
KwaZulu Natal stratified by number of symptoms reported at baseline. 95% Confidence 
intervals are given in ( ). 
 
Overall, there were no significant differences between the proportion of women BV positive 
and BV negative women presenting with symptoms p=0.53 [Ho: proportion (negative) – 
proportion (positive) = 0]. Women with laboratory diagnosed BV did not necessarily present 
with BV associated symptoms and laboratory diagnosed BV negative women could just as 
well present with BV associated symptoms, depicting lack of concordance between clinical 
symptoms and laboratory diagnosis.  
 
A comprehensive discussion of these results and their proposed significance is presented in the 
next chapter. 
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Chapter 4: Discussion 
The aim of this study was to measure the burden of BV and to determine factors associated 
with the disease in this area. Better understanding of risk factors will improve understanding 
of this complex disease which has poorly understood aetiology. This study confirms findings 
by other studies that there is a high prevalence of largely asymptomatic BV. The prevalence 
was just under 50% which is comparable with the rates obtained in non-pregnant women in 
the United States  and other developing countries [5, 7, 44] but higher than that obtained in a 
study in urban KwaZulu Natal [12]. The higher prevalence in this study might have been due 
to the use of the Ison and Hay diagnostic test with high specificity and sensitivity, compared to 
the Nugent’s criteria used in previously reported studies. This result confirms Ndlovu’s [36] 
concerns that in Africa BV prevalence might be vastly underestimated due to diagnostic 
challenges.  
 
At baseline, the median and mean ages were similar (34.9 vs. 35.0 years), showing that age 
distribution was symmetrically normally distributed. This study showed that a number of 
diverse risk factors including age were associated with prevalent BV.  Mean age between BV 
positive and negative women was similar, however after stratification of age into 35 and above 
and below 35 years old, BV was more prevalent in the older age group in the univariate 
analysis; women aged above 35 had a 27% higher odds of having BV compared to women 
aged 34 and below.. Interestingly this association was depended on education; in univariate 
analysis This association became statistically insignificant after controlling for education, 
although the size of the OR did not substantially change. The same loss of statistical 
significance after adjusting for age was true between BV and education. Interaction was then 
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further investigated based on the assumption that education is likely to vary depending on the 
age at initiation of the individual i.e. women below the age of 35 are more likely to have 
attended school compared to a 50 year old woman. A borderline significant interaction 
between age and education was detected, the inclusion of which significantly improved the 
model goodness of fit, with women aged 35 and above with secondary education being 51% 
(95% C.I: 0.26-0.95) less likely to have prevalent BV compared to younger women with only 
primary education. This might mean that older educated women lower their odds of having 
BV by virtue of having more reproductive health knowledge. For younger uneducated people 
the protective effect offered by age might be outweighed by lack of knowledge predisposing 
this group to BV. Worth noting is that beyond secondary level, education has no effect on BV. 
Hypothetically this may be extrapolated to mean that the basics of reproductive health are 
attained during secondary education after which a threshold on reproductive health 
improvement is reached. Alternatively this lack of effect may be attributed to the low numbers 
of people with tertiary education in this study group. 
 
In assessing employment as a binary yes/no variable, being employed had no effect on the 
odds of having BV compared to those unemployed. For those employed, type of employment 
was not significantly associated with BV before adjusting for other variables. After 
stratification of the employment variable into unemployment, housewife, employed and 
student categories, being a housewife [AOR 0.65 (95% C.I: 0.47-0.90)] or a student [AOR 
0.42 (95% C.I: 0.21-0.89)] significantly reduced the odds of having BV at baseline, compared 
to those unemployed. This protective effect persisted after controlling for factors such as age, 
education, infection with STIs and contraception use. Notably housewives did not perceive 
themselves as unemployed but they chose to stay at home ensuring the family’s welfare.  The 
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same applied with students who had elders looking after them. However caution must be taken 
when interpreting the result for students as these were young people in secondary education 
who might have been more protected against BV by virtue of their age and education [2, 4, 15, 
22, 37]. Comparing this group to older women who are presumably unemployed with lower 
education levels would clearly lead to a biased association between being a student and having 
BV compared to the unemployed. This is also noted by the decrease in statistical significance 
and widening of 95% C.I with introduction of age and education into the regression model 
with employment and BV. Nonetheless, the analysis showed that students had statistically 
significantly less chance of having prevalent BV after adjusting for other factors. 
 
Women from lower socio-economic status as measured by unemployment and fuel source 
(wood) for cooking were 41% more likely to present with BV. In the study area households 
that use wood for cooking are classified as the poorest. This data was also well correlated with 
data on house structure in terms of type of walls, roof and floor as well as number of assets in 
the household. These results echo results obtained in previous studies on the association 
between socio-economic status and BV [52, 53].  Women from disadvantaged socio-economic 
status are presumably less likely to negotiate condom use [54] as well as seek treatment for 
STIs leading to more BV cases in this group. In univariate analysis number of household 
assets was not associated with BV maybe owed to the fact that household assets may explain a 
household socio-economic status and not necessarily the individual’s, especially in adult 
women who may be living with extended family.   
 
Although it is well documented that a variety of intravaginal practices such as vaginal wiping, 
vaginal washing and insertion of substances into the vagina are common in several African 
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countries [24, 55], only 7 women reported using herbs or chemicals for cleaning or drying the 
vagina in this study group. Thus the data could not be used to assess the effects of these on 
vaginal flora. One possible explanation to this finding is that women under reported the use of 
inserts owing to the counselling against use of inserts during the screening visit prior to 
enrolment. This explanation is plausible  taking into account focus group discussions (analysis 
and results not presented in this report) where there was general consensus that inserts were 
used in this area with a reported 11% prevalence of inserts [54]. If there was no under 
reporting then it may be hypothesised that despite not using inserts, general reproductive 
health might be poor in terms of vaginal hygiene/cleanliness leading to high BV prevalence. 
 
In this study, results in line with previous studies were obtained on associations between BV 
and CT, TV and HSV2 [41, 52, 56, 57]. Women with TV were more than two and a half times 
as likely to present with concurrent BV infection. This may be due to TV infection altering the 
vaginal flora causing it to resemble BV, or BV related flora increasing the chances of 
acquiring TV. Studies have also reported that CT and NG are associated with BV, where 
women were less likely to resolve BV if they had NG and CT, hence implying that presence of 
an STI is causative of BV and not vice versa. [40, 52, 56]. The lactobacilli dominated vaginal 
ecology may be an important defence against pathogen acquisition by creating an acidic 
environment that is less hospitable to  invading pathogens [57]. Altering of this environment 
might inevitably lead to BV. One longitudinal study managed to establish the temporal 
relationship between BV and HSV2 and concluded that BV increases susceptibility to HSV2 
although they acknowledged that immunologic responses induced by genital tract infections 
may produce BV related vaginal environment [58]. Since our study was a cross-sectional 
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analysis, it was not possible to rule out reverse causality between BV and other STIs, 
consequently association does not imply causation in this study.   
 
Reported use of contraception was statistically significantly associated with a decrease in 
prevalent BV at baseline, with those on injectable contraceptives being 44% less likely to have 
a prevalent BV infection. Previous studies [44, 56, 59] have demonstrated that systemic 
hormonal contraception protects against BV due to an increase in estrogen, facilitating 
bacterial lactic acid production thus inhibiting BV associated micro organisms. Changes in 
vaginal mucosal immune cell populations indicative of altered local immune function may 
influence the risk of BV [56]. Injectable contraceptives may also modify BV by reducing 
menstrual frequency and volume, thus minimising vaginal flora disturbances, which are 
normally experienced during menstruation cycles. Whilst some studies have associated oral 
contraceptive with BV, in this study contraceptive pills and sterilisation were not significantly 
associated with BV. Condom use might have partially confounded the protective effect of 
injectable contraception by making it appear stronger. In univariate analysis with condom use 
as a type of contraception, women who reported use of injectables had a lower BV prevalence 
with a narrower OR confidence interval.  The OR for injectables slightly increased and the 95 
% C.I widening (0.44-0.79 compared to 0.48-0.91), after classifying condom as no 
contraception, talking into account that even women on other contraceptives did use condoms 
hence experienced the potentially protective effect conveyed by condoms.  
 
Previous studies have been inconsistent with regard to whether or not condom use is 
associated with BV. In the univariate analysis, reportedly always using a condom appeared to 
marginally decrease BV prevalence p=0.06. The association became significant after 
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controlling for other factors such as STIs and contraception. This may be due to the fact that 
the relationship between BV and specific risk factors such as sexual risk behaviour, hormonal 
contraception and condom use may not be entirely explained on the basis of their impact on 
lactobacilli [56, 60]. Multiple and diverse risk factors can contribute to BV acquisition. 
Condom use in the presence of an STI may be protective taking into account the association 
between STIs and BV, assuming that women who use condoms lower their risk of getting an 
STI and consequently BV. This would also explain the lack of a significant association in the 
univariate model without STIs. Inconsistent condom use had no effect on BV, which has been 
observed in previous studies on condom effectiveness [56, 60]. 
 
Not only was BV prevalence high in this population but so was the incidence with 81 cases 
per 100 women years. Incidence in this study population was higher than the 36 cases per 100 
women years obtained in a study in Pennsylvania [58] but lower than the 233 per 100 women 
year obtained in a small study of 96 women in Alabama [61] . About 50% of all women who 
were BV negative at baseline had at least one BV episode by week 52 and this is consistent 
with findings in a study in Pennsylvania [60] . The incidence rates remained generally high 
throughout the follow-up period, with about 20% becoming BV positive at each visit as was 
observed in a large 3 year follow-up study in Alabama [52]. BV can occur as an incident 
infection, re-infection, recurrent infection, persistent infection or as natural variability 
associated with the menstrual cycle [25]. These infections may occur at any given interval thus 
elevating the incidence of BV at all cohort periods. The proportion of BV positives generally 
decreased with increase in follow-up time, with a peak at week 40. The reduction may have 
been due to continual reproductive health counselling offered during the follow-up visits as 
part of the Microbicides trial [47]. The reasons for the peak are not quite well understood and 
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future longitudinal studies are required to investigate the possibility of cyclical trends in BV 
incidence. Interestingly this study shows that although BV prevalence in much higher in 
Africa compared to America, the incidence regimes mirror each other, which would imply that 
BV episodes in Africa may take much longer to resolve. Further longitudinal studies are 
required to assess duration and characteristics of BV episodes. 
 
In spite of the high laboratory BV prevalence, clinical presentation of symptoms was similar 
in both BV negative and positive women.  Only 9% presented with at least one symptom at 
baseline indicating that BV is largely asymptomatic in this area. Of the 52% who did not have 
BV, more than 50% had normal vaginal flora. Intemediate flora was quite common (19.5%) in 
the total population. Transient BV stage was not followed up in this study to see if it reverted 
back to normal flora or progressed to BV associated flora. The fact that BV is a common 
condition in Southern Africa, but largely asymptomatic   raises concerns especially in pregnant 
women in resource poor settings where diagnosis is made clinically. Many cases of BV 
potentially go undetected and untreated thus increasing the risk of pregnancy complications. 
The high BV prevalence and incidence in this area with a major HIV epidemic is of great 
concern considering that laboratory and longitudinal studies  have ascertained that BV 
promotes acquisition of HIV [40] thus the HIV infection attributable to BV might be high. In 
resource poor settings laboratory techniques such as microscopy should be employed for more 
vigorous BV screening and more accurate detection of asymptomatic BV in pregnant women 
and high HIV risk groups. 
 
Not only was a large proportion of BV asymptomatic but a fair proportion of BV negative 
women also presented with either one or more BV symptom. Similar to what was obtained in 
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a Gambian study [7], cervico-vaginal discharge was high in BV positive women maybe due to 
concurrent TV and NG infections, causing a medley of symptoms in BV positive women. 
Twenty four of the 45 participants with offensive discharge were BV negative, which might be 
attributed to the fact that detecting offensive or discoloured discharge through genital exam is 
highly subjective. Also worth noting is that it is possible that BV positive women internally 
washed the vagina in an effort to remove the smell and the discharge before attending clinic 
visits, resulting in the absence of symptoms on genital examination in this group.  
 
This study’s results showed no concordance between clinically diagnosed and laboratory 
diagnosed BV with the proportion of symptoms in both BV positive and negative women 
being statistically similar. This might have been due to the high proportion of BV grade II, 
which was not considered as definitive BV in line with accepted definitions[11]. Further 
characterisation of BV grade II is required to establish symptoms that are associated with this 
group, which will further inform if laboratory grade II should be clinically classified as BV 
negative or if both grades clinically present as BV. This supports the proposition that 
intermediate flora (BV grade II) precedes the development or follows the resolution of candid 
BV. It is hoped that diagnosis will improve with the introduction of molecular diagnosis of BV 
in developed countries [62, 63] and consequently improve BV screening and management.  
Limitations 
Possible Limitations 
The major limitation in determining the incidence of BV over the study period was the 
presence of the primary study product, 0.5% and 2% PRO2000/5 gels.  It is not possible to 
know who was on the product and who was on placebo before the study ends in 2009 as this 
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data will not be available for analysis until then. Thus the effect of the product on BV could 
not be determined. It was assumed that risk factors for BV remain the same for people on 
product and those on placebo, given that the study was double blinded, so although the overall 
incidence may be under- or over- estimated, risk factor analysis is unlikely to be affected. 
Prevalence estimates are not affected.  
 
As discussed in the literature review, diagnosis of BV is difficult, thus prevalence and 
incidence estimates might not be as accurate as would have been desired, due to non-
differential misclassification of diseased cases as non diseased. It was not possible to eliminate 
this bias. 
 
The effect of BV on HIV incidence during the trial could not be assessed as data on the HIV 
status was not available for analysis before the closure of the Microbicides trial. 
Possible sources of bias 
Selection bias might have been introduced since participants volunteered to join the study and 
those who volunteered might have been systematically different from those who did not and 
extrapolation might not be justifiable. Selection bias which could have been introduced by 
virtue of enrolling at the clinics, thus only taking those who are likely to attend at a health 
facility was controlled for by using snowball recruitment where participants would inform 
their immediate community about trial involvement. However only those who could access the 
clinic were enrolled hence still potential recruitment bias. HIV positive women were excluded 
from the study and this group might be systematically different from the HIV negative women 
thus making extrapolation to the general population unjustifiable.  
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Recall bias could not be eliminated since women were asked retrospectively for some data 
such as sexual behaviour. However the magnitude of this was limited due to the fact that most 
of the details required were current day to day activities. Reporter bias might have been 
present especially in terms of sexual behaviour questions with people tending to give socially 
acceptable answers; hence possibility of residual confounding could not be ruled out. There 
was also a considerable number of missing pH values for participants who presented with 
discharge causing non-differential misclassification. There was also possibility of 
measurement bias in assessment of clinical symptoms which might have led to non-differential 
misclassification in terms of disease status. This could not be controlled for in analysis thus 
much emphasis was put in training the clinical staff and laboratory staff and implementing 
quality control measures. 
 
Loss to follow-up bias might have been introduced during the trial period (prospective cohort) 
leading to an underestimation of the incidence rate. Pro-active tracking of participants was 
encouraged to minimise the loss to follow-up. Only a small number of women had reached 
week 52 when the data was extracted, resulting in an unreliably high period incidence at this 
time point. 
 
Possible sources of confounding 
Possible confounders include age, co-infection with TV, education, and religion. Information 
on these was collected during the course of the study through the use of structured 
questionnaires and controlled for during analysis by stratification and regression modelling. 
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Among the possible confounding variables, data was missing on the STI status in the male 
partner and therefore we used the STI status of the female as a surrogate marker for the male 
STI status. Smoking status which has been strongly linked with BV in several studies [59] was 
not collected, but in this community it is hugely unacceptable for women to smoke (personal 
communication: Misiwe Mzimela) thus the unmeasured confounding effect of smoking, if at 
all present, is negligible.  
 
By virtue of the baseline determinants analysis being cross sectional, association does not 
imply causation in any of these associations since temporal relationship is unknown.  
Strengths 
Strengths of this study include the study being a large longitudinal and complete dataset of a 
clearly defined population, with high retention up to week 40 of follow-up. This study looked 
at women with or without BV symptoms thus increasing generalisability of results for HIV 
negative women. There were consistent and standardized enrolment and data collection 
protocols. BV diagnostic techniques used were reliable, accurate and consistently quality 
controlled. Unlike this study, many studies have argued that levels of education and socio-
economic factors normally confound associations between BV and sexual behaviour and 
vaginal cleansing and African data on such variables has not always been entirely controlled 
for [7]. Our study included women from urban, peri-urban and rural settings and we could 
investigate the association between socio-economic, demographic, sexual practices and 
reproductive health variations with BV. In this epidemiological study, data on several 
confounding variables was collected and their effect assessed thus reducing the gap in public 
health knowledge and BV epidemiology.  
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Conclusions and Recommendations 
 
There is a high asymptomatic disease burden of BV in this area, making it a priority to 
accurately identify those at risk of BV since cases potentially go undetected thus increasing 
BV sequelae. Vigorous screening using microscopy in resource poor settings should be done 
considering that clinical diagnosis through symptoms may lead to under diagnoses of BV. 
 
The results presented here identify modifiable risk factors for BV which could inform 
interventions to improve vaginal health and decrease BV. These include condom use, 
injectable contraceptives, vaginal cleanliness and treatment of STIs. However use of injectable 
contraception should not preclude women from using barrier contraceptives to reduce the risk 
of acquiring HIV and other STIs. BV treatment during pregnancy, delivering general good 
vaginal hygiene practices in primary health care facilities and the inclusion of metronidazole 
in treatment of all women seeking STI treatment may potentially reduce this silent risk factor 
for HIV in people who are at high risk of HIV.  Further studies exploring the usefulness and 
cost effectiveness of artificial recolonisation of lactobacilli in the vaginal tract [24] are vital.  
 
This study confirms that diverse factors may work separately or in combination resulting in 
disruption of the vaginal biologic ecosystem. BV related factors must be tackled wholly in 
order to successfully control BV. Simple inexpensive strategies such as STI treatment and 
condom use, aimed at reducing BV must be implemented to reduce population attributable risk 
of BV for HIV and curb adverse pregnancy outcomes in this area of high HIV and BV 
prevalence and incidence. 
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Appendix B: Consent forms 
 
60 
 
 
61 
 
 
62 
 
 
 
 
 
63 
 
Appendix C: BV diagnosis 
 
Table C6: BV scoring by Ison and Hay method 
BV grade Interpretation “Clue” cells 
Grade 0 No bacteria Vaginal epithelial cells seen, but no bacteria seen 
Grade I Normal Predominantly Lactobacilli morphotypes seen. 
Lactobacillus morphotypes  
outnumber Gardnerella morphotypes 
Grade II Intermediate 
 
Mixed Lactobacillus and Gardnerella/Mobiluncus 
morphotypes seen. 
Usually 1- 15 Lactobacilli per high power field 
Ratio of Gardnerella/Mobiluncus to Lactobacilli less 
than 100 to 1 
Grade III BV positive Few or absent Lactobacillus morphotypes seen, but 
greatly increased numbers of Gardnerella vaginalis and 
other morphotypes seen.  
Ratio of Gardnerella/Mobiluncus to Lactobacilli more 
than 100 to 1 
Grade IV Gram-positive 
cocci 
Vaginal epithelial cells seen. No Lactobacillus or 
Gardnerella morphotypes seen. Gram positive cocci 
only 
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Appendix D: Case report  forms  for sexual behaviour, clinical and  laboratory data 
respectively 
 
Laboratory Results CRF 
MDP  301  –LABORATORY  RESULTS  Version  1  July  2005  Site name: AFRICA CENTRE Date of visit: 
// DD/MM/YYYY Screening number: 
 Initials:  Trial number: 
 LABORATORY RESULTS – ENROLMENT   
PROTOCOL PROCEDURES  
Pregnancy  
QuickVue or list if another test used:  
Name of test ______________________ Reason for use_____________  
___________________________________________________________  
Positive Negative 
Invalid   
HSV2  
Focus or list if another test used:  
Name of test ______________________ Reason for use_____________  
___________________________________________________________  
Positive Negative 
Equivocal   
>3.5 <1.0 1.0-3.5  
Index value ________________  
Syphilis RPR  
B&D MacroVue or list if another test used:  
Name of test ______________________ Reason for use_____________  
___________________________________________________________  
Positive Negative   
If positive, titre ___________________ 
Syphilis TPHA if RPR positive  
Omega Diagnostics Immutrep TPHA or list if another test used:  
Name of test ______________________ Reason for use_____________  
___________________________________________________________  
Positive Negative   
Trichomonas  
PCR or list if another test used:  
Name of test ______________________ Reason for use_____________  
___________________________________________________________  
Positive Negative   
Bacterial Vaginosis  
Ison and Hay score  
0 , I , II , III 
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, IV   
Neisseria gonorrhoea  
B & D Probe Tec or list if another 
test used:  
Name of test 
______________________ Reason 
for use 
_______________________________
______________  
Positive Negative  Equivocal  Inhibition  
Chlamydia trachomatis  
B & D Probe Tec or list if another 
test used:  
Name of test 
______________________ Reason 
for use   
Positive Negative  Equivocal  Inhibition   
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Sexual behaviour 
 
Interviewer: read the questions to the volunteer verbatim and allocate the correct answer from the selection, unless it is indicated that you 
read out each answer to the volunteer as well. Boxed type is the instructions to the interviewer. Type in italics is to be read to the volunteer.   
 
Sicela uphendule lemibuzo ngokucophelela ngoba izimpendulo zayo zibaluleke kakhulu emiphumeleni yalolucwaningo.  Khumbula ukuthi 
ulwazi osinikeza lona luzogcinwa luyimfihlo futhi luyosetshenziselwa kuphela izinjongo eziqondene nalolucwaningo.  
  
 
Section 1: Family planning  
 
1 
 
Njengamanje zikhona yini izindlela zokuhlela umndeni 
ozisebenzisayo? 
 
Yebo 
 
Cha 
  
  
 
→ Q. 1a 
 
→ Q. 1b 
1a Uma kunguyebo,yiziphi kulezizindlela ezilandelayo 
ozisebenzisayo?  
[Tick all that apply] 
 
Natural/rhythm 
   
→ Q. 2 
  
Pills 
 
Diaphragm 
 
Injectable Depo-Provera 
 
IUCD 
 
Condom (male or female) 
 
Traditional oral 
 
Sterilisation 
 
Other 
  
  
  
  
  
  
  
  
 
Foam/jelly/spermicide 
 
Injectable Nur-Isterate 
 
Injectable other (specify 
below if possible) 
 
Norplant implant 
 
Traditional vaginal 
 
Traditional other (specify 
below if possible) 
 
 
Specify_________________
_______________________ 
  
  
  
 
  
  
  
 
→ Q. 2 
 
→ Q. 2 
 
→ Q. 2 
 
 
→ Q. 2 
 
→ Q. 2 
 
→ Q. 2 
 
→ Q. 2 
 
1b 
 
Uma kungu cha, kungani ingekho indlela oyisebenzisayo 
yokuhlela umndeni? 
 
Uyancelisa 
   
  
Ufuna ukukhulelwa 
 
Usukhulile awusayi esikhathini 
 
Okunye  
 
  
  
  
 
Awusayi ocansini 
 
Sewavala inzalo (wena noma 
uphathina wakho) 
 
Chaza ____________________ 
  
  
 
 
2 
 
Zingaki izinsuku esezedlulile kusukela osukwini lwakho lokuqala lokuya esikhathini kulokhu kuya 
kwakho esikhathini okwedlule?  [List number, 99 if more than 3 months or 00 if menstruating now]  
   
 
 
2a 
 
Lokhukuya kwakho esikhathini 
kwakungesikhathi owawusilindele yini?   
 
Yebo 
 
       Cha 
  
  
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Section 2: Sexual activity and condom use 
 
Interviewer: please spend sometime ensuring that the volunteer understands what is termed by a sex 
act: one sex act is “penetrative vaginal sex that may or may not end up with ejaculation.”  
Also- don’t forget to probe for EXACT NUMBERS. 
 
“Manje sengizokubuza mayelana nokwenza kwakho ucansi nokusebenzisa kwakho 
amakhondomu. Sicela uphendule ngokweqiniso ngoba izimpendulo zakho zibaluleke kakhulu 
emiphumeleni yalolucwaningo.” 
 
 
3 
 
Njengamanje unaye yini uphathina wesilisa oya naye 
ocansini? 
  
 
 
Yebo 
 
Cha 
  
  
 
 
 
→ Q. 5 
Ensure that the volunteer understands what we mean by each category of partner. 
1) Long-term stable partners include some/most of the following characteristics: official marriage, 
traditional marriage, bride price paid, man known and accepted by woman’s family, have 
children together, live together, long-term relationship, man provides regular financial/material 
support, may be cohabiting or non-cohabiting. 
2) Other partners) includes all partners who do not fit into the first category above.  
 
4 
 
Luhloboluni lukaphathina onaye 
njengamanje?  
[Tick all that apply] 
 
Osekuqhutshekwe isikhathi eside nizwana 
naye noma nabo (1 noma ngaphezulu) 
 
Ezinye izinhlobo zomaqondana(1 noma 
ngaphezulu) 
  
 
  
 
 
5 
 
Zingaki izinsuku ezedlulile ugcinile 
ukuya ocansini? 
 
 
 
 
 
1 (lokhu 
kumbandakanya 
izolo, yilobusuku 
bayizolo, 
nanamhlanje) 
   
2 (kuthangi) 
   
  
3 
 
5 
 
7 
 
 
  
  
  
 
 
4 
 
6 
 
 
 
1-4 amasonto 
 
ngaphezu kwamasonto 
awu 4 
  
  
 
  
  
 
 
6 
 
Uyisebenzisile yini ikhondomu ngesikhathi ogcine 
ngaso ukwenza ucansi? 
  
Yebo 
 
Cha 
  
  
 
7 
 
Wawuneminyaka emingaki mhla uya ocansini okokuqala 
ngqa? 
 
Ngaphansi kweninyaka  
ewu 15  
   
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15 iminyaka kuya ku 19 weminyaka 
 
angikaze ngiye ocansini 
  
  
 
Iminyaka ewu 20 noma 
ngaphezulu 
 
Uyenqaba ukuphendula 
  
 
  
 
 
Section 3: Pregnancy test 
 
8 
 
Has urine sample been collected for pregnancy 
test? 
  
Yes 
 
No 
  
  
 
 
 
 
8a Why not?   
Not indicated in protocol schedule 
 
Not clinically indicated 
 
Not possible to obtain urine specimen  
 
Other 
 
(specify_______________________________) 
 
 
  
  
  
  
Interviewer code     
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Demographics 
 
Interviewer: read the questions to the volunteers verbatim and allocate the correct 
answer from the selection, unless it is indicated that you read out each answer to the 
volunteer as well. Boxed type is instructions to the interviewer. Type in italics is to be 
read to the volunteer. 
 
Section 1: Personal details 
 
1 
 
Usuku 
lokuzalwa    /  /     
            DD / MM / YYYY 
 
Noma iminyaka (uma usuku 
lokuzalwa  lungaziwa)    
 
2  
Yiluphi ulimi olukhulumayo ekhaya? 
 
________________________________________________ 
 
 
3 
 
Ukhonza kuliphi isonto/Iyiphi 
inkonzo ongaphansi kwayo? 
    
  
UngumKristu (oyiProtestani) 
 
UngumKristu (oyiKhatholika) 
 
UyiSeventh day adventist 
 
UyiMuslim 
 
UyiSayoni 
 
KoFakazi bakaJehova 
 
Okunye 
  
  
  
  
  
  
  
 
UngumKristu (ongachaziwe) 
                                 
Inkolo yesintu 
 
UngumKristu ozelwe  kabusha 
 
UyiHindu 
 
KwaShembe 
 
Akukho 
 
Chaza ______________________ 
  
  
  
  
  
  
Section 2: Education and sources of income 
“Manje ngizokubuza imibuzo ethize emayelana nezinga lemfundo yakho nokuthi imali engena 
emndenini wakho  itholakala kanjani. Lolulwazi aluyukusetshenziselwa okunye ngaphandle 
kokuba lube nomthelela ekucubunguleni imiphumela yalolucwaningo.  Sifuna ukubona ukuthi 
abantu abayingxenye yalolucwaningo kulelizwe bayafana yini nabangenele lolucwaningo 
kwamanye amazwe.”  
.  
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4 
 
Yiliphi izinga  eliphezulu lemfundo owalithola? 
  
Alikho    
   
Ngaya esikoleni kodwa angiqedanga izinga eliphansi 
 
Angiqedanga eSekhondari 
 
Angiqedanga esikhungweni semfundo ephakeme  
 
Angithandi ukuphendula 
 
  
  
  
 
Ngaqeda izinga eliphansi 
 
Ngaqeda eSekhondari 
 
Ngaqeda imfundo ephakeme 
 
Angiqedanga esikhungweni 
semfundo ephakeme  kodwa 
ngafundela umsebenzi  
 
 
 
 
 
 
 
 
5a Ungasichaza kanjani isimo sakho somsebenzi?   Ngiqashwe ngokugcwele    →Q. 5c 
                                                  
         
 Ngibambe itoho 
 
Ngisafuna umsebenzi  
 
Angiqashiwe 
 
Sengampesha  
 
Okunye 
  
  
  
  
  
→Q. 5c            Ngingumfundi  
 
Angivumi ukuphendula 
 
Ngihlala ekhaya 
 
 
 
 
Chaza_____________________
____________________ 
 
 
 
 
 
5b  
Ngonyaka odlule, ukhona umsebenzi owawuwenza?  
  Yebo 
 
Cha 
 
 
 
 
 
→Q. 6 
 
5c  
Chaza kafishane ngomsebenzi okuyiwona owenzayo noma owawuwenza.  Interviewer tick the answer most relevant to 
the description – make sure to only tick other if the participant’s work does not fit into any of the categories.   
 
  Umsebenzi ongafundelwa  
wamandla  
 
Ukulima izitshalo  
 
Ukudoba  
 
Okunye  
  
  
  
  
Ukudayisa/ukwenzela abanye 
umsebenzi othile 
 
Umsebenzi wasekhaya/endlini 
 
Ukufuya  
 
Ukukhiqiza izinto  
 
Chaza_____________________
____________________ 
 
 
 
 
 
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5d 
 
Ikuphi kulokhu okulandelayo 
okuwuchaza kangcono umsebenzi 
wakho? 
 
Ngihola njalo  
 
Ngiyitoho 
 
Angiholi nhlobo 
  
  
  
 
Ngiyazisebenza  
 
Ngihola ngesitokwe 
 
Okunye 
Chaza__________________ 
 
 
 
 
5e Wenzeka/wawenzeka  kuphi 
lomsebenz? [beka uphawu 
kukho konke okuyikho] 
Ekhaya 
 
Emgwaqweni  
 
Efemini 
 
Kwezokwakha/ezimayini/ 
enkwalini 
  
  
  
  
Emzini womqashi  
 
Esitolo/emakethe/endlwaneni 
yokuthengisela  
Emahlathini/epulazini/ 
engadini 
Okunye  
Chaza_____________________
__________________ 
 
 
 
 
 
Section 3: Housing and household 
"Manje sengizokubuza imibuzo ethile mayelana nomndeni wakho.  Uma sikhuluma ngomndeni sisho izindlu uqobo lwazo, 
nabantu bonke abayingxenye yalomuzi, kubala wena nabo bonke abahlala kuwo (abomndeni nezihlobo). Kungaba yindlu 
eyodwa noma izindlu eziningi kodwa kungezomndeni owodwa, noma ngabe lezizindlu zingasondelene.  Umndeni wakhiwe 
iqembu labantu, imvamisa abayizihlobo, abahlanganyelayo ekucazeleni abanakho futhi bavame nokudla ndawonye".
6 Ubani ongathi uyinhloko yomndeni?  
  Yimina     →Q. 8 
   
Uphathina  
 
Ingane 
 
Umzali 
 
Ezinye izihlobo 
 
Omunye 
 
  
  
  
  
 
Ingane yakwethu 
 
Umakoti/umkhwenyana 
 
Umamezala/ubabezala 
 
       Umshana (wesilisa/wesi 
                                   fazane) 
Chaza_____________________
___________________ 
 
 
 
 
 
→Q. 7a 
 
→Q. 7a 
 
→Q. 7a 
 
→Q. 7a 
 
→Q. 7a 
 
 
We would like to ask you some questions about the head of the household you have just identified.  
 
7a  
Ungasichaza kanjani isimo somsebenzi wenhloko 
yomndeni? 
  uqashwe ngokugcwele     →Q. 7c 
   
Uyitoho 
 
Ufuna umsebenzi  
 
Akaqashiwe 
 
Usewampesha 
 
Okunye 
  
  
  
  
  
 
→Q. 7c                     Umfundi  
 
Uyenqaba ukuphendula 
 
Owesifazane ongasebenzi 
 
Angazi 
 
Chaza_____________________
___________________ 
 
 
 
 
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7b  
Onyakeni odlule ngabe inhloko yekhaya ukhona yini 
umsebenzi eke yawenza? 
  Yebo 
 
Cha 
 
Angazi 
 
 
 
 
 
 
→Q. 8 
 
→Q. 8 
7c Chaza kafishane okuyiwona msebenzi obalulekile inhloko yekhaya evame ukuwenza noma eyake yawenza. Interviewer 
tick the answer most relevant to the description – make sure to only tick ‘ other’ if the work does not fit into any of the 
categories    
    Umsebenzi ongafundelwa  
wamandla  
 
Ukulima izitshalo  
 
Ukudoba  
 
Angazi 
 
Okunye  
  
  
  
  
  
Ukudayisa/ukwenzela abanye 
umsebenzi othile 
 
Umsebenzi wasekhaya/endlini 
 
Ukufuya  
 
Ukukhiqiza izinto  
 
(Chaza____________________
___________________) 
 
 
 
 
 
 
7d Ikuphi kulokhu okulandelayo 
okuwuchaza kangcono umsebenzi 
owenziwa inhloko yalomuzi? 
Ukukhokhelwa 
ngazozonke 
izikhathi 
 
itoho 
 
Akakhokhelwa 
 
Okunye 
  
 
  
 
  
 
Uyazisebenza 
 
Ukhokhelwa ngesitokwe  
 
Angazi 
 
(Chaza____________________
___________________) 
 
 
 
 
 
7e Ikuphi lapho wawuwenzela 
khona noma lapho 
osebenzela khona? [beka 
uphawu kukho konke 
okuyikhona] 
Endlini yasekhaya  
 
Emgwaqweni 
 
 
Embonini/efemini 
 
Ezindaweni 
zezinkontileka/emayini/ 
enkwalini  
 
Okunye 
  
  
  
  
 
  
 
Emzini womqashi  
 
Esitolo/emakethe/endaweni 
encane yokudayisela 
 
Ehlathini lokutshalwa/ 
epulazini/engadini 
 
Angazi 
 
(Chaza____________________
___________________) 
 
 
 
 
 
 
 
 
8  
Zingaki izindlu emzini wakho ezisetshenziselwa ukulala? 
 Yisho inombolo yazo   
Noma ubeke uphawu lapha uma 
ungafuni ukuphendula 
   
  
 
 
9  
Bangaki abantu abalala emzini wakho? 
 Isho inombolo yabo   
Noma ubeke uphawu lapha uma 
ungafuni ukuphendula 
   
  
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10 Uhlobo luni lomuzi ohlala kulo?  Endlini yomkhandlu 
wedolobha    
   
Indlu osayikhokhela ibhondi  
 
Efulethini osalikhokhela ibhondi 
 
Ekamelweni elingaphakathi noma 
elingaphandle kwendlu 
 
Okunye  
  
  
  
 
  
 
Endlini okhokha kuyo irenti  
 
Efulethini okhokha kulo irenti 
 
Emjondolo 
 
Chaza________________ 
  
  
  
 
10a Izindonga zendlu yakho 
zakhiwe ngani? 
Ngezitini zikasimende 
 
Ngothayela  
 
Ngamapulangwe 
 
Amatshe nosimende 
 
Okunye 
 
  
  
  
  
  
 
Ngamasoyi 
 
Ngowatela 
nokuphahlekwa/ngezintingo  
 
Notshani 
 
Ngama-prefab 
 
Amatshe nodaka 
  
  
 
  
  
  
 
  Chaza________________________    
10b Lwakhiwe ngani uphahla lwakho?  
Ukhethe  
 
Ngama-tiles 
 
Ngo-asbestos 
 
Okunye  
  
  
  
  
 
Utshani/umhlanga/amakhasi 
kabanana /ngoqwalo 
 
Chaza_____________________
____________________ 
 
  
 
 
10c Lakhiwe ngani 
iphansi? 
 
Amapulangwe angenziwe lutho 
 
Parquet/ipulangwe elipholishwayo 
  
Umata oyivinyl/imicwana yeasphalt  
 
U- carpet 
  
  
  
 
  
Umhlabathi/udaka/isihlabathi/u
bulongwe 
 
Usemende/ukhonkolo/isitini 
 
Amatiles ayiceramic/iterrazo 
 
Okunye 
Chaza_____________________
___________________ 
  
  
  
  
 
11 Ikuphi lapho nivamise ukuthola khona amanzi okuphuza emndenini njengamanje? ____________________ 
 
 
11a 
 
Ikuphi enikusebenzisa kakhulu ukwenza umlilo wokupheka? 
 
 
 
 
 
 
 
12  
Ubani ongumnikazi wendlu/wekhaya 
 
Uphathina    Imina    
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lapho uhlala khona? 
   
Umnikazi ndawo ozimele 
 
Umzali/abasemzini 
 
Esinye isihlobo 
 
Inkampani 
 
Okunye 
  
 
 
  
  
  
 
Owakwethu 
 
Uhulumeni/umkhandlu 
 
Uyenqaba ukuphendula 
 
 
Chaza_____________________
___________________ 
 
 
 
 
13 Umndeni wakho unakho yini lokhu okulandelayo: {beka uphawu olulodwa kulokho nalokho 
okuyimpendulo okusohlwini} 
  
  
Ugesi 
                                                     Umsakazo 
 
Umabonakude 
 
Ucingo 
 
Isiqandisi/ifiliji 
 
I-personal computer 
 
Umshini wokuwasha 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
  
  
  
  
  
  
  
 
Cha 
 
Cha 
 
Cha  
 
Cha 
  
Cha 
 
Cha 
 
Cha 
  
  
  
  
  
  
  
 
14 Ukhona yini oyilungu lomndeni wakho onalokhu: [beka uphawu olulodwa kuleyo naleyo mpendulo]   
  
Ibhayisikili 
 
Isithuthuthu /noma isikuta 
 
Imoto  
 
Imbongolo noma ihashi 
 
Izimvu noma izinkomo 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
 
Yebo 
  
  
  
  
  
 
Cha 
 
Cha 
 
Cha  
 
Cha 
 
Cha 
  
  
  
  
  
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Section 4- Access to resources 
15 Kulezizinyanga eziyi-12 ezedlule, ngabe wena nanoma iliphi ilungu lomndeni wakho nike 
nanikezwa yini incwajana ngudokotela yokuyothenga umuthi awunqumileyo kodwa   
anangakwazi ukuwuthola ngoba ningakwazanga ukuwukhokhela? 
                        
Yebo    
      
Cha 
 
Uyenqaba ukuphendula  
 
 
 
 
 
16 
 
Imali oyingenisayo emndenini ingakanani uma 
uyiqhathanisa naleyo umyeni/uphathina wakho 
ayingenisayo? 
 
Ngingenisa imali enkulu kunaye   
 
Ungenisa enkulu kuneyami 
 
Singenisa imali ecishe ilingane  
 
 
 
 
 
Interviewer code     
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  Genital Examination 
MDP 301 – Genital Examination  ‐ E1 Version 1.0 18 August 2005 Date of visit: Site name: AFRICA CENTRE – 
SOUTH AFRICA // Screening number: 
 Initials:  Trial number: 
 WK 0  4  8  12  16  20  24  28 
 32  36  40  44  48  52  Extra   
1. Was contact bleeding observed today (eg from speculum or cervical swab)? Yes  No   
2. Was cervicovaginal bleeding observed on exam today? Yes (complete table below)  No  
→Qn3a  
Describe  
Tick one box only  
Describe the source if this 
was identified  
Tick one box only  
Most likely explanation  
Tick one box only  
Relationship to study product 
Tick one box only  
Blood tinged discharge   
spotting   
bleeding   
profuse   
Discharge  Not identified 
  
Cervix (before swabbing) 
  
Cervical polyp   
Through cervical os   
Other__________________
___   
Menses  Infection   
Hormonal  Pregnancy 
  
Gel/product  Applicator 
  
Not sure   
Other__________________
_   
Unrelated   
Unlikely   
Possibly   
Probably   
Definitely   
If you observe bleeding and the participant hasn’t reported this, check with her and if she says ‘yes’ complete C1 and 
correct CS [or at week 0 correct Medical History and Log of Pre-existing conditions]. Remind her that it is important 
to note any genital symptoms including non-menstrual bleeding.  
If the bleeding is profuse (heavier than menses) and non-menstrual, complete a NAE form unless week 0 prior to gel.  
Report bleeding that is coming from a lesion under 5 or 6 or 8, not here.  
If NMB was reported at interview, but you do not observe any, go back and complete the ‘most likely explanation’ 
and ‘relationship’ on C1  
3a) Did you observe any unusual discharge today? Yes →Qn3b No →Qn4  
3b) What was the source of the discharge? Tick one box only Not possible to tell   
Vaginal  Cervical  Cervico-vaginal   
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3c) What was the pH of the vaginal discharge? ____._____ Not done in error   
3d) What were the characteristics of the discharge? Tick yes or no for each  
Curdlike Yes  No  Offensive Yes  No  Bloody Yes  No   
3e) Could the discharge be gel? Tick one box only Don’t know  Yes  No   
 
      4  What percentage of the cervical surface area was cervical ectopy? Answer even if no 
ectopy  
 
0% = no ectopy  1-25%  26-50%  51-100%   
 
 
 
 
Interviewer code     
 
